About Algeta
Algeta is a company based in Oslo (Norway) founded in 1997 was acquired by Bayer in December 2013. Algeta has raised $29 million across 1 funding round from investors including Bayer, Selvaag and SR One. Algeta operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Oslo, Norway
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Algeta As
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Algeta
Algeta has successfully raised a total of $29M through 1 strategic funding round. The most recent funding activity was a Series A round of $29 million completed in September 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Algeta
Algeta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer, Selvaag and SR One.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
A biotechnology venture capital firm investing in innovative science.
|
Locked | Locked | Locked | |
|
Wealth management and investment services are provided by NorgesInvestor.
|
Locked | Locked | Locked |
Investor details for Algeta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Algeta
Investment portfolio details for Algeta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Algeta
Detailed financials for Algeta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Algeta Comparisons
Peer comparison for Algeta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Algeta
Algeta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Algeta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Algeta
Complete news archive for Algeta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Algeta
Algeta was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Algeta is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Algeta is a funded company, having raised a total of $29M across 1 funding round to date.
Algeta was founded in 1997 in Oslo, Norway, as an oncology-focused company. Targeted therapies based on an alpha-pharmaceutical platform were developed for cancer patients. The lead product, radium-223 dichloride, was advanced through Phase III trials for castration-resistant prostate cancer with bone metastases. Thorium-227 conjugates linked to tumor-targeting molecules were explored in preclinical stages. Acquisition by Bayer occurred in December 2013.
Algeta's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Algeta has 5 investors. Key investors include Bayer, Selvaag, SR One, NorgesInvestor, and Healthcap.